Skip to main content

Table 3 Associations between KLK5 status and the clinicopathological variables of the breast cancer patients

From: Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions

  

No. of patients (%)

 

Variable

Total

KLK5 - negative KLK5 - positive

p value

Menopausal status*

    

Pre/peri

54

22 (40.7)

32 (59.3)

0.005b

Post

47

33 (70.2)

14 (29.8)

 

Gradec

    

I

3

1 (33.3)

2 (66.7)

 

II

30

21 (70.0)

9 (30.0)

0.34d

III

34

25 (73.5)

9 (26.5)

 

TNM Tumor size

    

<2 cm

26

17 (65.4)

9 (34.6)

 

2-5 cm

37

27 (73.0)

10 (27.0)

0.79d

> 5 cm

4

3 (75.0)

1 (25.0)

 

ER status

    

Negative

16

7 (43.8)

9 (56.3)

0.028b

Positive

51

39 (76.5)

12 (23.5)

 

PR status

    

Negative

24

15 (62.5)

9 (37.5)

0.42b

Positive

43

31 (72.1)

12 (27.9)

 
  1. a Cutoff point: 820 c/Kc equal to 70th percentile
  2. b Fisher's Exact Test
  3. c Bloom-Scarff-Richardson grading system
  4. d χ2 test
  5. cTNM system
  6. * In the total studied population